Novavax (NASDAQ: NVAX) and PAREXEL International Corporation (NASDAQ:PRXL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.
Valuation & Earnings
This table compares Novavax and PAREXEL International Corporation’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Novavax||$21.04 million||13.92||-$186.64 million||($0.77)||-1.31|
|PAREXEL International Corporation||$2.10 billion||2.12||$342.80 million||$2.34||37.50|
PAREXEL International Corporation has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than PAREXEL International Corporation, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and target prices for Novavax and PAREXEL International Corporation, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|PAREXEL International Corporation||1||9||2||0||2.08|
Novavax presently has a consensus price target of $5.31, suggesting a potential upside of 425.52%. PAREXEL International Corporation has a consensus price target of $73.71, suggesting a potential downside of 16.01%. Given Novavax’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Novavax is more favorable than PAREXEL International Corporation.
This table compares Novavax and PAREXEL International Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|PAREXEL International Corporation||5.12%||28.68%||8.11%|
Volatility and Risk
Novavax has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, PAREXEL International Corporation has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.
Institutional and Insider Ownership
50.5% of Novavax shares are held by institutional investors. Comparatively, 91.6% of PAREXEL International Corporation shares are held by institutional investors. 4.0% of Novavax shares are held by insiders. Comparatively, 2.9% of PAREXEL International Corporation shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
PAREXEL International Corporation beats Novavax on 7 of the 13 factors compared between the two stocks.
Novavax Company Profile
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
PAREXEL International Corporation Company Profile
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries. Its segments include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI). The CRS segment includes various phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. The PC segment provides technical expertise and advice in areas, such as strategy, drug development, regulatory affairs, strategic compliance and targeted communications services in support of product launch. The Company’s PI segment provides information technology solutions.
What are top analysts saying about Novavax Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novavax Inc. and related companies.